DERMTECH INC (DMTK) Stock Price, Quote, News and Overview
NASDAQ:DMTK - Nasdaq - US24984K1051 - Common Stock - Currency: USD
DMTK Quote, Performance and Key Statistics
0.094
-0.01 (-11.32%)
The current stock price of DMTK is 0.094 USD. In the past month the price decreased by -73.14%. In the past year, price decreased by -96.38%.
DMTK Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About DMTK
Company Profile
DermTech, Inc. engages in the development and sale of products for the diagnosis and treatment of skin diseases. The company is headquartered in San Diego, California and currently employs 278 full-time employees. The company went IPO on 2017-06-20. The firm is focused on developing and marketing non-invasive genomics tests to aid in the diagnosis and management of skin cancer, inflammatory skin diseases, and aging-related skin conditions. Its technology enhances early melanoma detection by non-invasively detecting genomic markers associated with melanoma to identify higher risk lesions at their earliest stages to rule out melanoma. The company provides genomic analysis of skin samples collected non-invasively using its Smart Stickers. Its DermTech Melanoma Test (the DMT) facilitates the clinical assessment of pigmented skin lesions that raise the concern for melanoma. Its commercial test addresses unmet needs in the diagnostic pathway of pigmented skin lesions, dark-colored patches of skin often referred to as moles. The company markets the DMT under the name Pigmented Lesion Assay (PLA). The company is also focuses on products to assess precancerous genomic changes associated with UV sun exposure.
Company Info
DERMTECH INC
12340 El Camino Real
San Diego CALIFORNIA 92037 US
CEO: John Dobak
Employees: 278
Company Website: https://dermtech.com/
Phone: 18584504222
DERMTECH INC / DMTK FAQ
What is the stock price of DERMTECH INC today?
The current stock price of DMTK is 0.094 USD. The price decreased by -11.32% in the last trading session.
What is the ticker symbol for DERMTECH INC stock?
The exchange symbol of DERMTECH INC is DMTK and it is listed on the Nasdaq exchange.
On which exchange is DMTK stock listed?
DMTK stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for DERMTECH INC stock?
6 analysts have analysed DMTK and the average price target is 1.53 USD. This implies a price increase of 1527.66% is expected in the next year compared to the current price of 0.094. Check the DERMTECH INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is DERMTECH INC worth?
DERMTECH INC (DMTK) has a market capitalization of 3.29M USD. This makes DMTK a Nano Cap stock.
How many employees does DERMTECH INC have?
DERMTECH INC (DMTK) currently has 278 employees.
Is DERMTECH INC (DMTK) expected to grow?
The Revenue of DERMTECH INC (DMTK) is expected to grow by 16.8% in the next year. Check the estimates tab for more information on the DMTK EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy DERMTECH INC (DMTK) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of DMTK, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of DMTK, evaluating the profitability, health, valuation and growth aspects
- DERMTECH INC (DMTK) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- DERMTECH INC (DMTK) Sales and EPS estimates to see what analysts future expectations are.
- DERMTECH INC (DMTK) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- DERMTECH INC (DMTK) Insider and Institutional Ownership to learn about the owners and their transactions.
- DERMTECH INC (DMTK) Stock Chart to make your own analysis
- DERMTECH INC (DMTK) Latest news and press-releases to stay up to date.
Does DERMTECH INC (DMTK) stock pay dividends?
DMTK does not pay a dividend.
When does DERMTECH INC (DMTK) report earnings?
DERMTECH INC (DMTK) will report earnings on 2024-08-01, after the market close.
What is the Price/Earnings (PE) ratio of DERMTECH INC (DMTK)?
DERMTECH INC (DMTK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.7).
DMTK Technical Analysis
DMTK Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DMTK. Both the profitability and financial health of DMTK have multiple concerns.
DMTK Financial Highlights
Over the last trailing twelve months DMTK reported a non-GAAP Earnings per Share(EPS) of -2.7. The EPS increased by 30.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -87.04% | ||
| ROE | -224.09% | ||
| Debt/Equity | 0 |
DMTK Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to DMTK. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 35.19% and a revenue growth 16.8% for DMTK